The FDA also notes that adverse events from state-licensed 503A pharmacies are likely underreported because these facilities generally aren't required to submit adverse events directly to the FDA - meaning the documented numbers are a floor, not a ceiling
You should NOT take GLP-1 medications if you have: personal or family history of medullary thyroid carcinoma or MEN2 syndrome, severe gastroparesis, or active pancreatitis
Whilst some ingredients such as BHB salts can temporarily raise blood ketone levels, this does not reliably translate into meaningful fat loss, and most weight loss claims for these ingredients are not authorised by UK or EU regulatory bodies
Switching recommendations for patients taking OZEMPIC 0.25 mg, 1 mg or 2 mg subcutaneously once weekly to RYBELSUS (formulation R2) are not available
For many people, digestive side effects are most noticeable early on and while the dose is being increased, and they tend to ease as the body adjusts